These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1367 related articles for article (PubMed ID: 21635994)

  • 1. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
    Lee EK; Revil C; Ngoh CA; Lister J; Kwon JM; Park MH; Park SJ; Park YS; Shin SJ; Lee MA; Lee NS; Zang DY; Bae EJ; Kang MJ
    Clin Ther; 2012 Jun; 34(6):1408-19. PubMed ID: 22657254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    Tikhonova IA; Huxley N; Snowsill T; Crathorne L; Varley-Campbell J; Napier M; Hoyle M
    Pharmacoeconomics; 2018 Jul; 36(7):837-851. PubMed ID: 29498000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
    Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
    Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J; Díaz-Rubio E
    Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
    Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
    Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
    Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
    J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
    Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
    Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
    Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
    Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
    Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.